{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Solid+Tumor+Cancers&page=5", "query": { "condition": "Metastatic Solid Tumor Cancers", "page": 5 }, "page_size": 10 }, "pagination": { "page": 5, "page_size": 10, "total_count": 1751, "total_pages": 176, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Solid+Tumor+Cancers&page=6&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Solid+Tumor+Cancers&page=4&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-14T03:19:01.353Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07404332", "title": "5-Azacitidine Plus PD-1/PD-L1 Inhibitor With PD-1/PD-L1 Refractory Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor", "Locally Advanced Solid Tumor", "Metastatic Tumor" ], "interventions": [ { "name": "5 Azacytidine", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Cemiplimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mohammed Milhem", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 35, "start_date": "2026-02-11", "completion_date": "2031-02-28", "has_results": false, "last_update_posted_date": "2026-05-28", "last_synced_at": "2026-10-14T03:19:01.353Z", "location_count": 1, "location_summary": "Iowa City, Iowa", "locations": [ { "city": "Iowa City", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT07404332" }, { "nct_id": "NCT05945823", "title": "Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Locally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer", "Esophageal Adenocarcinoma", "Esophageal Squamous Cell Cancer", "Siewert Type 1 GEJ Cancer", "Pancreatic Cancer" ], "interventions": [ { "name": "Futibatinib", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "5-FU", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Levoleucovorin", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Taiho Oncology, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 53, "start_date": "2023-07-13", "completion_date": "2027-01", "has_results": false, "last_update_posted_date": "2026-09-01", "last_synced_at": "2026-10-14T03:19:01.353Z", "location_count": 16, "location_summary": "Santa Monica, California • Denver, Colorado • Miami Beach, Florida + 13 more", "locations": [ { "city": "Santa Monica", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Miami Beach", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT05945823" }, { "nct_id": "NCT06031441", "title": "A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Locally Advanced Solid Tumors", "Recurrent Solid Tumors", "Metastatic Solid Tumors" ], "interventions": [ { "name": "RO7566802", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 65, "start_date": "2023-11-27", "completion_date": "2027-03-03", "has_results": false, "last_update_posted_date": "2026-07-28", "last_synced_at": "2026-10-14T03:19:01.353Z", "location_count": 6, "location_summary": "Birmingham, Alabama • New Haven, Connecticut • New York, New York + 3 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "New York", "state": "New York" }, { "city": "Columbus", "state": "Ohio" }, { "city": "Harrisburg", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT06031441" }, { "nct_id": "NCT03849469", "title": "A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Melanoma", "Cervical Carcinoma", "Pancreatic Carcinoma", "Triple Negative Breast Cancer", "Hepatocellular Carcinoma", "Urothelial Carcinoma", "Squamous Cell Carcinoma of the Head and Neck", "Nasopharyngeal Carcinoma", "Renal Cell Carcinoma", "Non-small Cell Lung Carcinoma", "Small Cell Lung Carcinoma", "Gastric or Gastroesophageal Junction Adenocarcinoma", "Advanced or Metastatic Solid Tumors", "Prostate Carcinoma", "Epithelial Ovarian Cancer", "Fallopian Tube Cancer", "Primary Peritoneal Carcinoma", "Intrahepatic Cholangiocarcinoma", "Squamous Cell Anal Cancer", "Squamous Cell Penile Carcinoma", "Squamous Cell Vulvar Carcinoma", "Colorectal Carcinoma", "Endometrial Carcinoma" ], "interventions": [ { "name": "XmAb®22841", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab (Keytruda®)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Xencor, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 78, "start_date": "2019-05-29", "completion_date": "2023-02-16", "has_results": false, "last_update_posted_date": "2023-03-30", "last_synced_at": "2026-10-14T03:19:01.353Z", "location_count": 28, "location_summary": "Encinitas, California • La Jolla, California • Los Angeles, California + 15 more", "locations": [ { "city": "Encinitas", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03849469" }, { "nct_id": "NCT00740805", "title": "Veliparib, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Non-Hodgkin Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Ann Arbor Stage III Non-Hodgkin Lymphoma", "Ann Arbor Stage IV Non-Hodgkin Lymphoma", "Solid Neoplasm" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin Hydrochloride", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Veliparib", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 81, "start_date": "2008-08-18", "completion_date": "2026-10-22", "has_results": false, "last_update_posted_date": "2026-08-19", "last_synced_at": "2026-10-14T03:19:01.353Z", "location_count": 1, "location_summary": "New Brunswick, New Jersey", "locations": [ { "city": "New Brunswick", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00740805" }, { "nct_id": "NCT00014456", "title": "Combination Chemotherapy Plus Filgrastim in Treating Patients With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Bladder Cancer", "Breast Cancer", "Carcinoma of Unknown Primary", "Esophageal Cancer", "Gastric Cancer", "Head and Neck Cancer", "Lung Cancer", "Melanoma (Skin)", "Ovarian Cancer", "Pancreatic Cancer", "Prostate Cancer", "Sarcoma" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "docetaxel", "type": "DRUG" }, { "name": "gemcitabine hydrochloride", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Dartmouth-Hitchcock Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2000-03", "completion_date": "2005-10", "has_results": false, "last_update_posted_date": "2013-08-28", "last_synced_at": "2026-10-14T03:19:01.353Z", "location_count": 1, "location_summary": "Lebanon, New Hampshire", "locations": [ { "city": "Lebanon", "state": "New Hampshire" } ], "official_url": "https://clinicaltrials.gov/study/NCT00014456" }, { "nct_id": "NCT04919811", "title": "Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non Small Cell Lung Cancer" ], "interventions": [ { "name": "Taletrectinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Nuvation Bio Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 217, "start_date": "2021-09-01", "completion_date": "2027-12", "has_results": false, "last_update_posted_date": "2026-01-07", "last_synced_at": "2026-10-14T03:19:01.353Z", "location_count": 20, "location_summary": "Beverly Hills, California • Glendale, California • La Jolla, California + 17 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Glendale", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04919811" }, { "nct_id": "NCT05933265", "title": "Study of LP-184 in Patients With Advanced Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumor", "Metastatic Solid Tumor", "GBM", "TNBC - Triple-Negative Breast Cancer", "NSCLC", "Pancreatic Adenocarcinoma", "DDR Gene Mutation" ], "interventions": [ { "name": "LP-184", "type": "DRUG" }, { "name": "Olaparib", "type": "DRUG" }, { "name": "Nivolumab & Ipilimumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Lantern Pharma Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 64, "start_date": "2023-06-09", "completion_date": "2026-07-28", "has_results": false, "last_update_posted_date": "2026-05-04", "last_synced_at": "2026-10-14T03:19:01.353Z", "location_count": 7, "location_summary": "Springdale, Arkansas • Indianapolis, Indiana • Louisville, Kentucky + 4 more", "locations": [ { "city": "Springdale", "state": "Arkansas" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT05933265" }, { "nct_id": "NCT02706392", "title": "Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hematopoietic and Lymphoid Cell Neoplasm", "Malignant Solid Neoplasm", "Metastatic Lung Non-Small Cell Carcinoma", "Metastatic Triple-Negative Breast Carcinoma", "Recurrent Acute Lymphoblastic Leukemia", "Recurrent Mantle Cell Lymphoma", "Refractory Chronic Lymphocytic Leukemia", "Stage III Lung Non-Small Cell Cancer AJCC v7", "Stage IIIA Lung Non-Small Cell Cancer AJCC v7", "Stage IIIB Lung Non-Small Cell Cancer AJCC v7", "Stage IV Breast Cancer AJCC v6 and v7", "Stage IV Lung Non-Small Cell Cancer AJCC v7", "Unresectable Lung Non-Small Cell Carcinoma" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "ROR1 CAR-specific Autologous T-Lymphocytes", "type": "BIOLOGICAL" } ], "intervention_types": [ "OTHER", "BIOLOGICAL" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 21, "start_date": "2016-03-16", "completion_date": "2021-09-28", "has_results": true, "last_update_posted_date": "2022-08-31", "last_synced_at": "2026-10-14T03:19:01.353Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT02706392" }, { "nct_id": "NCT07228247", "title": "A Phase Ⅰ/Ⅱa Study of HMPL-A251 in Participants With Advanced or Metastatic HER2-expressing Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumors, Adult" ], "interventions": [ { "name": "HMPL-A251", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hutchmed", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 147, "start_date": "2025-12-16", "completion_date": "2028-12-31", "has_results": false, "last_update_posted_date": "2026-09-22", "last_synced_at": "2026-10-14T03:19:01.353Z", "location_count": 8, "location_summary": "Denver, Colorado • Plantation, Florida • Tamarac, Florida + 4 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Plantation", "state": "Florida" }, { "city": "Plantation", "state": "Florida" }, { "city": "Tamarac", "state": "Florida" }, { "city": "East Brunswick", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT07228247" } ] }